Genocea Biosciences develops vaccines based on a platform that reduces the time to discover vaccine candidates. Among the company’s co-founders are Darren Higgins, Ph.D. Professor of Microbiology and Molecular Genetics and David Sinclair, Ph.D., Professor of Pathology, both at Harvard Medical School. The company was founded based on developments at both Berkeley and Harvard.
From the company’s press release:
Genocea Biosciences Inc., a vaccine discovery and development company pioneering a new class of T cell-based vaccines, today announced that it has closed a $35 million Series B round of venture financing, with new investors Johnson & Johnson Development Corporation (JJDC), Skyline Ventures and MP Healthcare Venture Management, Inc. (MPH) joining existing investors Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures. Stephen J. Hoffman, M.D., Ph.D., managing director at Skyline Ventures, joins the Genocea board in connection with the financing. In addition, Genocea also announced the appointment of industry veteran Seth Hetherington, M.D., to chief medical officer. read full press release